 |
|
|
|
 |
|
|
| Article 1 to 10 out of 46 concerning Frost & Sullivan
|
-
European telemedicine vendors adapt to advances in technology
(07/10/2008)
Telemedicine market will generate $236.0 million by 2014
Although the European telemedicine industry has achieved significant progress, certain technological advances have inadvertently led to new hurdles. These include the greater need for standards and physician acceptance of novel telemedicine ...
-
PACS to change the future of european medical imaging industry
(07/09/2008)
There are significant opportunities in the European picture archiving and communication system (PACS) market for vendors who can provide customised solutions and products that support enhanced workflows.New analysis from Frost & Sullivan, European ...
-
Western European in vitro diagnostics market sustained by new technologies
(07/02/2008)
Market earns $12.65 billion in 2014
Despite issues such as rising R&D costs, poor reimbursement and a decline in prices, the emergence of new technologies is boosting the Western European in vitro diagnostics (IVD) markets. While the introduction of automation and integrated platforms ...
-
Product Development is the way Forward in the European Radiopharmaceuticals Market
(12/14/2007)
A spate of installations of positron emission tomography (PET) and PET/computed tomography (CT) diagnostic scanners has given a new lease of life to the mature, but far from saturated European radiopharmaceuticals market. These installations have ...
-
Extensive Proteomics Research Strengthens the Uptake for Protein Purification Kits in Europe
(12/05/2007)
The growing need for the production of more proteins within faster timelines is forcing laboratories to look for better expression systems and automated solutions to meet their demands. This increasing need to identify and understand proteins is ...
-
Early Diagnosis and Targeted Therapy to Address Unmet Need in European Breast Cancer Therapeutics Market
(11/07/2007)
The greatest unmet need of all breast cancer patients is a cure. A variety of drugs are used to treat breast cancer in stages III and IV. However, they only act to control the progression of the disease and can be associated with side effects that ...
-
Development of effective, novel treatments critical to ensure growth in the european bladder cancer therapeutics market
(10/05/2007)
None of the developments in the bladder cancer area have improved the long-term survival rate of patients, with research results also remaining disappointing. Patients still die from muscle invasive disease, despite aggressive therapy with curative ...
-
Targeted Therapies Driving the European Head and Neck Cancer Therapeutics Markets
(09/26/2007)
Despite improvements in surgical techniques and the development of novel chemoradiotherapy strategies, survival rates in patients with head and neck cancer has remained relatively unchanged over the last 30 years. While this could be due to the ...
-
Coagulation Testing in Europe Shifts towards Point-of-care testing to Generate Quick Results and Improve Patient Care
(08/24/2007)
Coagulation testing is a common practice used for patients under oral anticoagulation therapy as well as those undergoing cardiac surgeries including cardiopulmonary bypass surgery. The early monitoring of anticoagulants during or before surgery is ...
-
Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis
(07/24/2007)
According to Frost & Sullivan, the European endometriosis therapeutics market will experience sustained growth in the coming years. Rising awareness about the condition coupled with the anticipated launch of improved products will be the major ...
Additional information
Frost & Sullivan
London, United Kingdom
Company
Articles
|
|
|
|
|
|
Top
